Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expanded Payor Coverage, Broader Pharmacy Access And New Channel Partnerships

The Company recently secured additional payor coverage representing approximately 12.5 million incremental covered lives, including expanded access through Medicare Part D supplement plans and other commercial and government-sponsored healthcare channels. These additions build upon Scienture's existing reimbursement footprint and further increase patient access to Arbli™ nationwide.

In addition to expanding coverage, Scienture is working to strengthen Arbli™'s commercial infrastructure by targeting the expansion of pharmacy participation, relationships with pharmacy buying groups, specialty technology participation, and distribution capabilities. The Company is also advancing initiatives that are expected to increase Medicaid access and expand Arbli™'s presence across additional healthcare channels.

"Expanding patient access remains one of our highest priorities as we continue to commercialize Arbli™," commented Narasimhan Mani, President and co-CEO of Scienture. "The addition of approximately 12.5 million covered lives, coupled with our growing pharmacy network, specialty technology relationships, and channel partnerships, represents another important step in increasing awareness, availability, and utilization of Arbli™. We expect that these initiatives will strengthen our commercial infrastructure and position us to drive increased prescription volume across multiple healthcare channels."

Arbli™ is a proprietary oral suspension formulation of losartan potassium designed to improve patient access and compliance, particularly among pediatric, geriatric, and other patient populations with difficulty swallowing tablets, within the approximately $219 million U.S. losartan market, representing approximately 72 million prescriptions annually (IQVIA MAT Apr 2026). By eliminating the variability and inconvenience associated with pharmacy compounding, Arbli™ delivers a consistent, convenient, and scalable solution for healthcare providers.

"With approximately 72 million losartan prescriptions written annually in the United States and a market of$219 million, we believe Arbli™ has a substantial commercial opportunity ahead," stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. "Importantly, our strategy does not depend on capturing a large share of the overall market. Even modest penetration among patients who require or prefer a ready-to-use oral liquid formulation could represent a meaningful revenue opportunity. As we continue expanding coverage, pharmacy access, and distribution channels, we believe we are building a strong foundation for long-term prescription growth and value creation."

About Arbli™

Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
  
  
  
   
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
  
  
  
   
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
  
  
  
   

IMPORTANT SAFETY INFORMATION

• Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
  
  
  
   
• Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).
  
  
  
   
• Do not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in patients with severe hepatic impairment.
  
  
  
   
• The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.